How does capivasertib work at the target level?
Capivasertib is an ATP-competitive inhibitor of the AKT kinases (commonly described as AKT1/2/3) within the PI3K/AKT signaling pathway. By blocking AKT activity, it reduces downstream phosphorylation signaling that supports tumor cell survival and growth [1].
What pathway does it affect downstream of PI3K/AKT?
When PI3K signaling activates AKT, activated AKT then drives multiple survival and proliferation processes through downstream targets. Capivasertib’s inhibition of AKT is designed to shut down that downstream signaling cascade, which can make tumor cells more vulnerable, including in settings where tumors rely heavily on AKT pathway activity [1].
Why does blocking AKT matter in cancer?
Many cancers develop resistance to therapies by keeping PI3K/AKT signaling active even when upstream signals are blocked. Targeting AKT directly aims to counter that kind of pathway reactivation by inhibiting a key signaling node that multiple upstream inputs converge on [1].
What kind of inhibition is it (and what does that imply)?
Capivasertib inhibits AKT by competing with ATP at the kinase active site. ATP-competitive kinase inhibitors typically act by directly preventing phosphorylation of AKT substrates, which is the functional step that propagates the signaling pathway [1].
Where is capivasertib typically positioned therapeutically?
Capivasertib is most often discussed for solid tumors where PI3K/AKT pathway activation is important, and it has been studied in combination strategies intended to improve response durability by attacking signaling at the AKT node [1].
---
Sources
[1] DrugPatentWatch.com – Capivasertib (search result page)